Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2023 Lymphoma & CLL Highlights
25 January 2024 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in lymphoma & chronic lymphocytic leukemia (CLL) from ASH 2023
The Post-ASH 2023 Lymphoma and CLL Highlights was supported by Genentech, Abbvie, AstraZeneca, Bristol Myers Squibb and Genmab. Supporters have no influence over the production of content.
Lymphoma
Session 1: CAR-T therapy
ZUMA-12: axi-cel as first-line therapy in pts with HR LBCL
Julio Chavez Moffitt Cancer Center, Tampa, FL, United States
ALLO-501/501A: ALLO-647 for lymphodepletion
Frederick Locke Moffitt Cancer Center, Tampa, FL, United States
TRANSCEND FL: liso-cel as second-line therapy in pts with HR R/R FL
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion: CAR-T in lymphoma
Lymphoma
Session 2: Bispecifics
EPCORE NHL-5: epcoritamab + lenalidomide for R/R DLBCL
Won-Seog Kim Samsung Medical Center, Seoul, Korea, Republic of
Glofitamab for R/R LBCL previously treated with CAR-T
Lorenzo Falchi Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Glofit + R-CHOP for previously untreated HR LBCL
Lorenzo Falchi Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Panel discussion: bispecifics
Lymphoma
Session 3: Bispecific combinations
M-Pola in elderly unfit/frail pts with DLBL
Adam Olszewski Brown University, Providence, RI, United States
Smart Stop: Lenalidomide, tafasitamab, rituximab, + acalabrutinib for DLBCL
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
AFM13 with P+E CB-derived NK cells for CD30+ lymphomas
Yago Nieto The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion: Bispecific combinations
Lymphoma
Session 4: BTKs
BRUIN: pirtobrutinib in R/R MCL pts with prior cBTKi
Jonathon Cohen Winship Cancer Institute of Emory University, Atlanta, GA, United States
NX-5948 for R/R B-cell malignancies
Alexey Danilov City of Hope, Duarte, CA, United States
Panel discussion: BTKs
Lymphoma
Session 5: Novel therapies
CIT and novel therapies in 2L+ for R/R aggressive LBCL
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
VALENTINE-PTCL01: valemetostat in pts with R/R PTCLs
Steven Horwitz Memorial Sloan Kettering Cancer Center, New York City, NY, United States
KT-333 for R/R lymphomas and LGL-L
Aditi Shastri Albert Einstein College of Medicine, New York City, NY, United States
Panel discussion: Novel therapies
CLL
Session 6: Personalized therapy
NCRI FLAIR: I+V is superior to FCR and is a new SOC for 1L CLL
Peter Hillmen University of Leeds and Leeds Teaching Hospitals NHS Trust, United Kingdom
FLAIR: PB MRD levels to predict BM uMRD4
Andrew Rawstron Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
CLL2-BAAG: acalabrutinib, venetoclax and obinutuzumab for R/R CLL
Moritz Fürstenau University of Cologne, Cologne, Germany
CAPTIVATE: ibrutinib + venetoclax as first-line treatment for CLL/SLL
Paolo Ghia Vita-Salute San Raffaele University, Milan, Italy
Panel discussion: personalized therapy
CLL
Session 7: Novel therapies & combinations
TRANSCEND CLL 004: Liso-Cel in R/R CLL/SLL
Tanya Siddiqi City of Hope, Duarte, CA, United States
BGB-11417-101: BGB-11417 + zanubrutinib for TN-CLL/SLL
Chan Yoon Cheah Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
BOVen for treatment-naive TP53-mutant mantle cell lymphoma
Anita Kumar Memorial Sloan Kettering Cancer Center, New York City, NY, United States
GAIA/CLL13: venetoclax combinations in tit pts with CLL
Moritz Fürstenau University of Cologne, Cologne, Germany
Panel discussion: novel therapies & combinations
The Post-ASH 2023 Lymphoma & CLL Highlights has been supported by:
